Navigation Links
Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
Date:4/29/2008

CAMBRIDGE, Mass., April 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the first quarter ended March 31, 2008. At March 31, 2008, Idenix's cash, cash equivalents and marketable securities totaled approximately $99.0 million.

2008 Year-to-Date Business Highlights

-- Idenix reported positive data from an ongoing phase I/II study of

IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being

developed for the treatment of HIV-1. In the first dosing cohort of

this study, eight HIV-1 infected treatment-naive patients receiving 800

mg of IDX899 once-daily achieved a median reduction in plasma virus

levels of approximately 2.0 log10, or 99 percent, after seven days of

treatment. The 400 mg cohort of this study is now complete and dosing

has been initiated in the 200 mg cohort. To date, no serious adverse

events have been reported and no patients have discontinued from the

study. Data from this clinical trial have been submitted for

presentation at scientific meetings this summer.

-- The company continued to make progress with its hepatitis C discovery

and development programs, having presented data from preclinical

studies of its lead nucleotide prodrug candidate, IDX184, and potential

clinical candidates from its protease inhibitor program at the annual

meeting of the European Association for the Study of the Liver (EASL)

last week. (Please see Idenix press releas
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
2. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
3. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
4. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
5. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
9. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
10. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
11. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... Bridgewater, New Jersey location received ... Administration (FDA) relating to an inspection in June 2014 ... injectable, which was divested to Galderma S.A. in July ... contract manufacturers (rather than Valeant,s own internal manufacturing) with ...
(Date:9/30/2014)... -- The Eastern European medical device industry is in ... as new medical-device manufacturers are constantly trying to penetrate ... to reduce the cost incurred for placing their products ... effective means to achieve this target. This research service ... and provides profiles of key distributors in ...
(Date:9/30/2014)... , Sept. 30, 2014   Decision ... patient-level claims data, anemic chronic kidney disease non-dialysis ... erythropoiesis-stimulating agent (ESA) medication. In addition, one-year persistency ... Other key findings from the ... An Analysis of Erythropoiesis Stimulating Agents in Late ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
... On Friday, April 20, 2012, at 8:30 a.m. Eastern/2:30 ... Inc.,s (CTI) (NASDAQ and MTA: CTIC) management team will ... first quarter achievements and financial results. ... Central European/5:30 a.m. Pacific Time 1-800-762-8779 (US Participants) ...
... 2012  Watson Pharmaceuticals, Inc. (NYSE: WPI ) ... version of FORTAMET® (metformin hydrochloride extended-release tablets) as part ... the product today. FORTAMET® is indicated as an adjunct ... patients 17 years of age or older. ...
Cached Medicine Technology:Watson Launches Generic FORTAMET(R) 2
(Date:9/30/2014)... some stickleback fish fathers can have long-term effects on ... dads cause their offspring to behave in a way ... changes are accompanied by changes in gene expression, the ... the Proceedings of the Royal Society B: Biological ... moms are very important for their offspring," said ...
(Date:9/30/2014)... Asheville, North Carolina (PRWEB) September 30, 2014 ... cloud readiness and IT Infrastructure analytics across data ... announced it has achieved an important milestone of ... problems and plan for important projects such as ... workload migrations. , The strong customer engagement ...
(Date:9/30/2014)... 2014 Speaking on this occasion, ... ‘Nursing Conference’ as a remarkable event, which brings together ... and clinical research and diagnostic companies, leading universities and ... perfect platform to share experience, foster collaborations across industry ... Nursing Conference is a forum to explore issues of ...
(Date:9/30/2014)... 2014 MyMobileUni seeks to partner globally ... have similar shared vision to transform individuals and empower ... (MMU):, , to impact ... all ages , to have focused channels ... to promote equal access to education and ...
(Date:9/30/2014)... with bowel cancer for a genetic condition would cut ... new research has found. , In a major study, ... and researchers from the University of Exeter,s Medical School ... for a genetic condition known as Lynch Syndrome. ... by changes in genes which check the spelling in ...
Breaking Medicine News(10 mins):Health News:In stickleback fish, dads influence offspring behavior and gene expression 2Health News:In stickleback fish, dads influence offspring behavior and gene expression 3Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 3Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 2Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 3Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 2Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 3Health News:Genetic test would help 'cut bowel cancer spread' 2Health News:Genetic test would help 'cut bowel cancer spread' 3
... one species of bacteria could be more persistent and ... other, encouraging it to bolster its defenses. Interrupting ... these infections. Researchers from Wake Forest University Baptist ... , the online open-access journal of the American Society ...
... ... Boise, Idaho acupuncture clinic, recently relocated to a larger office and more convenient ... acupuncture clinic is now located in very close proximity to one of the ... licensed acupuncturists and 2 massage therapists working collaboratively to help patients get and ...
... 2010 Elsevier, the world-leading publisher of scientific, technical ... Society of Geriatric Oncology (SIOG) announced today the launch ... www.geriatriconcology.net ). The journal is focused on advancing ... of older adults with cancer. It covers all ...
... ... health care organizations better comply with OASIS-C and improve staff performance and patient outcomes ... new and updated patient and caregiver teaching resources. , ... (PRWEB) July 6, 2010 -- Pritchett & Hull ...
... Site ... ... Surgery (ASAPS) is proud to introduce Project Beauty , a new consumer website, that ... one the leading medical authorities in Beauty - The American Society for Aesthetic Plastic Surgery., , ...
... ... Though Advanced Software Testing Services and Methodologies , ... Naples, FL (PRWEB) July 6, 2010 -- QualEDIx, a ... ICD-10 software testing services network is pleased to announce that healthcare industry veteran, Larry ...
Cached Medicine News:Health News:Bacterial communication encourages chronic, resistant ear infections 2Health News:Boise Acupuncture Clinic Grows into Larger Office 2Health News:Elsevier and International Society of Geriatric Oncology launch Journal of Geriatric Oncology 2Health News:Aesthetic Society Launches Project Beauty, ,NEW Consumer Website Covering All Things Beauty, 2Health News:Aesthetic Society Launches Project Beauty, ,NEW Consumer Website Covering All Things Beauty, 3Health News:Larry Watkins Joins QualEDIx as Executive Vice President, Healthcare Strategy and Business Development 2Health News:Larry Watkins Joins QualEDIx as Executive Vice President, Healthcare Strategy and Business Development 3
This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 20-200 microliter range....
... and density. Proven ergonomic design reduces hand fatigue, prevents injury. Dry seal ... 20-200 ... 1.0~2.0 Imprecision(%) ... 1 Dimensions: ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,411-9) or contact custom...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: